#Canada #Montreal #ExCellThera #UM171 #Medexus

ExCellThera and Medexus: A Groundbreaking Licensing Agreement

In a promising development for hematological cancer treatments in Canada, ExCellThera Inc. has announced exclusive licensing and supply agreements with Medexus Pharmaceuticals. This strategic partnership involves the commercialization rights for Zemcelpro® (dorocubicel), better known as UM171 Cell Therapy, specifically aimed at treating serious blood malignancies such as leukemias and myelodysplasias.

The Collaborative Venture

ExCellThera, recognized as a leading entity in blood stem cell technology, along with its subsidiary, Cordex Biologics, is set to advance its product's reach within the Canadian market. The partnership with Medexus, a company proficient in hematology and oncology, promises to establish a robust framework that will facilitate innovative treatment solutions for patients with significant unmet medical needs. According to David Millette, CEO of Cordex, this collaboration marks a milestone not just for companies involved but more importantly, for patients who are urgently in need of new treatment options.

Vision for Treatment

Zemcelpro® is distinct as it employs a unique method of producing personalized, cryopreserved hematopoietic stem cell transplants. This innovative product consists of two components: UM171-expanded CD34+ cells and unexpanded CD34- cells, extracted from a single cord blood unit. The therapy targets individuals facing hematological malignancies who lack suitable donor cells, thus presenting a critical option for patients requiring allogeneic stem cell transplantation.

The current stage of development indicates that commercialization in Canada may not commence before 2028, pending approval from Health Canada. As part of the regulatory strategy, Medexus plans to seek official branding approval of Zemcelpro®.

Strategic Importance of the Agreement

The agreement delineates a shared economic interest, with royalties on net sales and milestone payments set to create a productive economic relationship between ExCellThera and Medexus. Not only does this partnership signify a promising future for Canadian patients battling blood cancers, but it also represents an expansion of Cordex's global commercialization strategy. Millette emphasized the importance of pursuing additional strategic partnerships globally, aiming to improve patient access to transformative therapies worldwide.

Both ExCellThera and Medexus are poised to collaborate closely, with Cordex continuing to manage the clinical program and ensuring the supply chain for Zemcelpro®. The goal remains clear: to deliver innovative, life-enhancing therapies to the individuals who need them most.

Research and Development Insights

Zemcelpro® has recently gained conditional marketing authorization from the European Commission for treating adults with hematological malignancies in need of stem cell transplants. Key clinical trials in the U.S., Europe, and Canada have evaluated the product's safety and effectiveness, with over 120 patients involved in various stages of testing. Remarkably, the therapy has already achieved orphan drug designations and other recognitions from regulatory agencies, highlighting its potential impact on current treatment paradigms.

With extensive plans for future regulatory submissions not only in Canada but also in the U.S., U.K., and Switzerland, the momentum around Zemcelpro® is building effectively. These ongoing endeavors underscore the dedication of ExCellThera and Medexus to expanding patient access and enhancing treatment options in the landscape of blood diseases.

Conclusion

The newly forged alliance between ExCellThera and Medexus could change the trajectory for many patients suffering from aggressive blood cancers. By leveraging advancements in cell therapy, this partnership addresses an urgent medical necessity, fostering hope and paving new avenues for treatment. As the landscape for cancer therapy continues to evolve, the dedication of these companies toward patient-centered solutions remains steadfast.